Management of Recurrent Vaginitis

Robert L. Holley, MSc, MD
Professor
Division of Urogynecology and
Pelvic Reconstructive Surgery
Dept of Obstetrics and Gynecology
UAB School of Medicine



Objectives

After hearing this presentation, the participant should:

- Understand vaginal physiology in the asymptomatic patient
- Be aware of recommended treatments for the three most common causes of vaginitis in the acute and recurrent clinical setting
- Be informed of other vaginal disorders that pose management challenges

Disclosure Statement

Neither myself or any member of my family have a financial arrangement related to the content of this activity or any supporters of this program

Scope of the Problem

- Vaginitis most common reason for patient visits to obstetricians and gynecologists in the USA
- Estimated 20 million office visits annually
- One billion dollars in direct costs for yeast infections annually
- Vulvodynia estimated to occur in 15% of gynecologic patients

Accuracy of Patient Self-diagnosis of Vulvovaginal Candidiasis (VVC)

Vulvovaginal candidiasis33.7%Bacterial vaginosis18.9%Trichomoniasis2.1%Mixed vaginitis21.1%Normal flora13.7%Other (dermatoses, etc)10.5%

Ferris, DG et al. Obstet Gynecol, 2002


Accuracy of Physician Diagnosis of Vaginitis via Saline Wet Mounts


Vulvovaginal candidiasis 39.6%

Trichomoniasis 75.0%

Bacterial vaginosis 76.5%

Ferris, DG et al. J Family Prac, 1995







Dr. Holley 2/21/2016

If vaginal pH is >5.0 the possibilities are:


- bacterial vaginosis
- Trichomonas vaginalis
- menopause on no hormone replacement
- presence of blood in vagina
- breastfeeding on demand
- presence of topical vaginal medications
- recent intercourse with semen in vagina




















| Longitudinal Study of Vaginal Yea Non-pregnant Wom | |
|--|------------------------------|
| 248 women 18-25 years of age 60% Caucasian, all from Pittsburgh | area |
| • Cultures for yeast at enrollment, 4, 8, and 12 • 98% of positive cultures C. albicans | months |
| | |
| Results: 70% colonized at one point or another, most Only 4% colonized at all 4 visits Independent risk factors for vaginal yeast colo | nization: |
| 70% colonized at one point or another, most Only 4% colonized at all 4 visits Independent risk factors for vaginal yeast colo Marijuana use in past 4 mo. | nization: P=.001 |
| 70% colonized at one point or another, most Only 4% colonized at all 4 visits Independent risk factors for vaginal yeast colo Marijuana use in past 4 mo. DMPA use in post 4 mo. | nization: |
| 70% colonized at one point or another, most Only 4% colonized at all 4 visits Independent risk factors for vaginal yeast colo Marijuana use in past 4 mo. | nization: P=.001 P=.02 |

What is the Utility of Yeast Cultures?

- To identify non C. albicans yeasts i.e.
 C. glabrata, etc., that don't respond to conventional therapies
- To prove or disprove yeast colonization in a persistent, symptomatic patient
- Test of cure in a treated patient

Vulvovaginal Candidiasis Therapy Uncomplicated Fluconazole (Diflucan) 150mg oral, single dose, provides therapeutic vaginal concentrations for up to 72 hours - Intravaginal miconazole, clotrimazole, terconazole, butoconazole (all imidazole antifungals are fungistatic, may be fungicidal at high doses) Pregnancy, topical (vaginal) azoles for 7 days Note: Drugs that may have clinically important interactions with fluconazole: - Calcium channel blockers - Astemazole - Warfarin - Cyclosporin A - Phenytoin - Tacrolimus Theophylline

Centers for Disease Control and Prevention, STD Treatment Guidelines, 2015

Rifampin

| Vulvovaginal Candidiasis Therapy |
|--|
| Complicated/Recurrent/Persistent |
| Clinical Pearl Patients presenting with longstanding symptoms of pruritus, burning, often taking polypharmacy of meds for presumed yeast Need a "wash out" period of at least 4 weeks of no meds Then evaluate with exam, culture, and if positive: |
| Fluconazole 200 mg orally every 3 days for 3 doses Evaluate again in 4-6 weeks, exam, re-culture If positive, consider maintenance fluconazole 150 mg weekly, clotrimazole 500 mg vaginally weekly |

Second most common yeast causing symptoms in USA Seen more commonly in diabetes, immunocompromise Filaments or pseudohyphae not seen on KOH or saline preps; small oval or round spheres Diagnosis most often made by culture Not usually associated with "cottage cheese" discharge Treatment Boric acid vaginal suppositories (600 mg in size 0 gelatin capsule, once or twice vaginally for 15-20 days) Re-culture as test of cure, consider maintenance therapy with 600 mg boric acid vaginally 2-3 x weekly Additional strategies for presistent C. glabrata 17% flucytosine in vaginal cream 3-4% amphotericin vaginal cream

Vaginal Trichomoniasis Trichomonas vaginalis, flagellated protozoa first described in 1836 3 million cases reported annually in the USA Asymptomatic in 50% of women 30% eventually develop symptoms

Trichomonas Vaginalis

Usually copious, foul smelling discharge

Vaginal/vulvar discomfort, burning, dyspareunia

Vagina with marked inflammation, many white blood cells, pH >4.5, epithelium often covered with petechial hemorrhages

T. vaginalis - Diagnosis



- Motile Trichomonads on saline wet mount makes diagnosis secure, but
- Wet mount has a sensitivity of 60-80% compared to culture
- More than 10³/ml live protozoa are required for detection via wet mount

Hook, E. Sex Trans Dis, 1999 Ryu, JS et al. Yonsei Med J, 1999


Trichomonas Vaginalis - Therapy

- Metronidazole 500 mg orally twice daily for 7 days
 - or

2 grams orally, single dose

- Tinidazole 2 grams orally single dose
- 90-95% cure rate if sex partner treated
- 75-80% if partner not treated
- Pregnancy T. vaginalis associated with adverse pregnancy outcomes; PROM, pre-term delivery, low birth weight. CDC recommends 2 gram oral single dose of metronidazole for symptomatic pregnant women regardless of pregnancy stage
- Side effects of metronidazole
 - Metallic or bitter taste
 - Nausea, vomiting
 - Emetic effect with alcohol
 - Rarely, pancreatitis, blood dyscrasias

Centers for Disease Control and Pre



Trichomonas Vaginalis Alternative Therapies for Recurrent Cases

- Tinidazole (Tindamax) 2 grams oral dose
 - Longer half life (12-14 hours) than metronidazole (6-7 hours)
 - Fewer side effects
 - Drug levels in tissue close to levels in serum
- Clotrimazole (Gyne-Lotrimin)
 - Cures in 48-66% of women intravaginal suppositories for 6 nights
- Paromomycin 6.25% cream, must be compounded, one 4 gram application nightly for 2 weeks, mild vaginal burns, cures in 75% of patients with metronidazole intolerance or resistant Trich.

Hager, WD, Sex Trans Dis, 200 Nyirjesy, P et al, Clin Infec Dis, 199

Bacterial Vaginosis

Normal Vaginal Ecosystem

10⁵⁻⁶ bacteria/gram of secretion Lactobacillus dominant pH = 3.5 - 4.5

Inhibition of anaerobes by lactic acid, hydrogen peroxide

Bacterial Vaginosis

109 - 1011 bacteria/gram Lactobacilli absent Abundant anaerobes Bacteroides sp. Prevotella Peptostreptococci Mobiluncus Gardnerella Mycoplasmas

pH >4.5

Biswas MK, Clin Obstet Gynecol, 1993

Bacterial Vaginosis (BV)

Asymptomatic in 50% of women 15% of private gynecology patients 10-30% of pregnant women 5-25% of college students

Predisposing Factors

Douching
Antibiotics
Foreign bodies (tampons, diaphragms)
Exposure to semen
Menses
Multiple sexual partners
Concomitant STD's, esp. T. vaginalis
Early coital experience

Bacterial Vaginosis - Not a Benign Condition

Strong association between BV and:

- Premature rupture of membranes
- Preterm labor
- Chorioamnionitis
- Postpartum endomyometritis
- Post-cesarean wound infection
- Pelvic inflammatory disease
- Post hysterectomy vaginal cuff infection

Sweet, RL Am J Obstet Gynecol, 1993 Soper, DE et al. Am J Obstet Gynecol, 1990

Bacterial Vaginosis - Diagnosis

Amsel criteria - three of four must be positive

- Vaginal pH >4.5
- Abnormal, malodorous vaginal discharge
- Amine odor on addition of 10% KOH
- Presence of clue cells on saline wet mount

Amsel, R et al. Am J Med, 1983

Diagnosis of BV - Clue Cells on Micro

But also,

look between the cells

- No lactobacilli
- No leukocytes

Clinically:

- No redness, inflammation
- Insignificant host immune response



Bacterial Vaginosis - Therapy

- Metronidazole 500 mg orally twice daily x 7 days
- Metronidazole gel 0.75% one full application (5 grams) vaginally once daily x 5 days
 or
- Clindamycin cream 2%, one full application (5 grams) vaginally at bedtime x 7 days

Alternative Regimens

- Tinidazole 2 grams orally once daily x 2 days
- Tinidazole 1 gram orally once daily x 5 days
- or
- Clindamycin 300 mg orally twice daily x 7 days Note:

Treatment recommended for all symptomatic pregnant women, either oral or vaginal regimens

Centers for Disease Control and Prevention, STD Treatment Guidelines, 2015

Persistent/Recurrent BV

- In 30-40% of women who respond to treatment, BV recurs within 3 months
- No convincing evidence that BV is a sexually transmitted disease.

Treatment of male partners has not improved cure rates or reduced recurrences

 Alternate therapies (acidic douches, lactic acid gels, probiotics) have generally been ineffective

> Fredricsson, B et al. Gynecol Obstet Invest, 1989 Holley, RL, Schwebke JR, Sex Trans Dis, 2004

Biofilms as a Cause of Recurrent BV

- Certain strains of Gardnerella vaginalis form biofilms, a dense web of bacterial cells encased in a fibrillar exopolysaccharide network
- These biofilms increase bacterial resistance to host immune defenses, pH extremes and antimicrobial agents
- This appears to be the prime mechanism for the relative resistance to metronidazole and high recurrence rate in patients prone to bacterial vaginosis

Patterson, JL et al, Am J Obstet Gynecol, 2007 Swidsinki, A et al, Am J Obstet Gynecol, 2008

| Recurre | ent Bact | terial V | 'aginosis |
|---------|----------|----------|-----------|
| | | | |

Recommended Maintenance Regimens

- Initial 10 day course of metronidazole gel 0.75% followed by met gel twice weekly for 4 months Results: Infection recurred in 26% of met gel vs 59% of placebo patients (P=.001) Sobel, JD et al, Am J Obstet Gynecol, 2006
- Metronidazole or tinidazole 500 mg twice daily for 7 days followed by 21 days of 600 mg boric acid vaginally, followed by twice weekly met gel for 16 weeks Results: cumulative cure at 12, 16, and 28 weeks from initial visit was 87, 78, and 65%, respectively with failure rate of 50% by 36 week follow-up Reichman, O et al., Sex Trans Dis, 2009

Non-Vaginitis Vaginitis

Clinical scenario

Healthy pre-menopausal woman with longstanding vaginal itching, non-malodorous discharge, usually polypharmacy Exam: excellent vaginal estrogen effect, no inflammation, saline wet mount → healthy vaginal squames, no vaginitis organisms, no WBC reaction, negative yeast culture

Diagnosis: Excess physiologic vaginal secretions

Treatment: Reassurance

· Another scenario -

Same patient, same exam, totally negative wet mount, cultures Treatment: Patient will not accept "normal" convinced that something is wrong, wants medication

Assessment: Somatization due to stress, unhappiness

- Neurosis
- Avoidance of sexual intimacy with partner
- Patient usually poorly accepts need for counseling, anxiolytics, antidepressants

Dr. Holley 2/21/2016

